Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | EDNRB | P24530 | 2/20 | 0.49 |
| ▸ | EDNRA | P25101 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6855189 | 0.97 | DRD4 (0.53) | MAPTDRD4MAPK14PPARGDRD2 | |
| SCHEMBL6857506 | 0.81 | EDNRB (0.52) | PPARGEDNRBEDNRA | |
| SCHEMBL6851387 | 0.79 | MAPK8 (0.49) | PPARGF10EDNRBEDNRAHDAC1 | |
| SCHEMBL6851276 | 0.78 | EDNRB (0.52) | MAPTPPARGEDNRBEDNRA | |
| SCHEMBL6858292 | 0.74 | MAPT (0.49) | MAPTDRD4DRD2HTR2AF10 | |
| SCHEMBL6858382 | 0.73 | PPARG (0.76) | MAPTPPARGEDNRBEDNRA | |
| SCHEMBL6858332 | 0.73 | PPARG (0.50) | MAPTPPARGF10EDNRBEDNRA | |
| SCHEMBL6858309 | 0.73 | EDNRB (0.50) | MAPTEDNRBEDNRAALDH1A1 | |
| SCHEMBL7188348 | 0.73 | EDNRB (0.64) | MAPTEDNRBEDNRAALDH1A1 | |
| SCHEMBL6307109 | 0.73 | EDNRB (0.64) | MAPTF10EDNRBEDNRAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787651-B2 | 2-CARBOXY-SUBSTITUTED; TREATING OSTEOPENIA, OSTEOPOROSIS, CANCER, DIABETES AND ATHEROSCLEROSIS. | SMITHKLINE BEECHAM CORPORATION | 2004-09-07 | — | — | US | disclosed |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | PPARG, PPARA, PPARD | MAPT 3447/4885DRD4 1709/4885MAPK14 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.